SGLT2 inhibitors and GLP-1 receptor agonists are used in patients with type 2 diabetes as
glucose lowering therapies, with additional benefits of weight loss and blood pressure …

Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

Abstract The American Diabetes Association and the European Association for the Study of
Diabetes convened a panel to update the prior position statements, published in 2012 and …

The discovery of glucagon-like peptide-1 (GLP-1), an incretin hormone with important effects
on glycemic control and body weight regulation, led to efforts to extend its half-life and make …

Abstract The American Diabetes Association and the European Association for the Study of
Diabetes convened a panel to update the prior position statements, published in 2012 and …

Background Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has
neuroprotective effects in preclinical models of Parkinson's disease. We investigated …

In healthy individuals, the incretin hormone glucagon-like peptide 1 (GLP1) potentiates
insulin release and suppresses glucagon secretion in response to the ingestion of nutrients …

In order to ensure normal body function, the human body is dependent on a tight control of
its blood glucose levels. This is accomplished by a highly sophisticated network of various …

Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analogue that binds to serum
albumin in vivo and is approved for once-daily treatment of diabetes as well as obesity. The …

GLP-1, a peptide hormone secreted from the gut, stimulating insulin and suppressing
glucagon secretion was identified as a parent compound for novel treatments of diabetes …